Notification letter to registered shareholders and reply form
Filed with HKEX · Stock code 3692 · · 2 pages · English and Chinese
The English and Chinese versions of the Company’s Current Corporate Communications are now available on the Company’s website at www.hspharm.com and the website of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) at www.hkexnews.hk respectively (the “Website Version”). The Company strongly recommends you to access the Website Version of the Current Corporate Communications and all fu
Hansoh Pharmaceutical Group Company Limited on 6ix
Earlier from Hansoh Pharmaceutical
- Interim report 2026
- Voluntary announcement - risvutatug rezetecan for injection (HS-20093) for osteosarcoma included in priority review and approval procedure of the nmpa
- Hansoh Pharmaceutical Group: Pharma announces pivotal phase 3 clinical trial of HS-10374 in the treatment of adults with moderate-to-severe plaque psoriasis met the co-primary endpoints
- Voluntary announcement - the phase iii clinical study of HS-10374 in the treatment of moderate-to-severe plaque psoriasis has met the co-primary endpoints
- Voluntary announcement - the clinical trial approval for HS-20197 for injection issued by the national medical products administration
Later from Hansoh Pharmaceutical
- Notification letter to non-registered holders and request form
- Voluntary announcement - biologics license application of risvutatug rezetecan for injection (HS-20093) for osteosarcoma accepted by the nmpa
- Voluntary announcement - update on the marketing authorization status of aumolertinib in the EU
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement - marketing authorization application of Aumolertinib in the EU resubmitted and validated by the EMA
Follow Hansoh Pharmaceutical into a list and get an email when it puts out news.
Follow Hansoh Pharmaceutical